Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Itacitinib adipate (INCB-39110) is under development for the treatment ...

Although many of the solvents used to swell GPEs are mixtures of flammable organic solvents (such as dimethyl carbonate), there are many potential non-reactive, low vapor pressure solvents that could ...